title: 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
abstract: BACKGROUND
  In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life. However, there are several drawbacks including therapeutic failure and cardiotoxicity. We evaluated the efficacy and toxicity of combination chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR), medroxyprogestrone acetate (MPA) and mitoxantrone hydrochloride (MIT).
  
  
  METHODS
  Sixteen patients with advanced or recurrent breast cancer were enrolled. Chemotherapy was given in a 28-day cycle, starting with MIT 10 mg/m2 intravenously on day 1, then oral 5'-DFUR 800 mg and MPA 800 mg daily. Two or more cycles were given.
  
  
  RESULTS
  Fifteen patients were assessable for response and toxicity. Thirteen patients had been treated previously with an anthracycline containing regimen and 2 with CMF. There were 2 partial response patients (13.3%) and 1 complete response patient (6.7%). There were 11 patients showing no change (NC) (73.3%), one of whom was a minor responder and 7 with a long period of NC. There was only one with progressive disease patient. The overall response rate was 20.0%. Adverse events occurred in 5 patients (33.3%). Myelosuppression was the most common with 5 patients becoming leukopenic (33.3%). Nausea/vomiting was the second most common side effect, affecting 2 patients (13.3%).
  
  
  CONCLUSIONS
  Given its high efficacy and preservation of QOL, the combination of MIT, 5'-DFUR and MPA can be a 2nd or 3rd line therapy for advanced or recurrent breast cancer, especially for anthracycline-resistant cases.
authors.affiliation: Department of Surgery I, National Defense Medical College, 3-2 Namiki, Tokorozawa City, Saitama 359-8513, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: H
authors.initials: H
authors.lastname: Hiraide
authors.forename: S
authors.initials: S
authors.lastname: Tamakuma
authors.forename: T
authors.initials: T
authors.lastname: Tabei
authors.forename: M
authors.initials: M
authors.lastname: Maruyama
authors.forename: M
authors.initials: M
authors.lastname: Touma
authors.forename: H
authors.initials: H
authors.lastname: Okamura
authors.forename: F
authors.initials: F
authors.lastname: Matsumoto
authors.forename: S
authors.initials: S
authors.lastname: Akao
authors.forename: H
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yagi
authors.forename: H
authors.initials: H
authors.lastname: Mochizuki
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016879:Salvage Therapy; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D005467:Floxuridine; D008942:Mitoxantrone; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine